Literature DB >> 22745307

Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension.

Kewal Asosingh1, Samar Farha, Alan Lichtin, Brian Graham, Deepa George, Micheala Aldred, Stanley L Hazen, James Loyd, Rubin Tuder, Serpil C Erzurum.   

Abstract

Hematopoietic myeloid progenitors released into the circulation are able to promote vascular remodeling through endothelium activation and injury. Endothelial injury is central to the development of pulmonary arterial hypertension (PAH), a proliferative vasculopathy of the pulmonary circulation, but the origin of vascular injury is unknown. In the present study, mice transplanted with BM-derived CD133(+) progenitor cells from patients with PAH, but not from healthy controls, exhibited morbidity and/or death due to features of PAH: in situ thrombi and endothelial injury, angioproliferative remodeling, and right ventricular hypertrophy and failure. Myeloid progenitors from patients with heritable and/or idiopathic PAH all produced disease in xenografted mice. Analyses of hematopoietic transcription factors and colony formation revealed underlying abnormalities of progenitors that skewed differentiation toward the myeloid-erythroid lineage. The results of the present study suggest a causal role for hematopoietic stem cell abnormalities in vascular injury, right ventricular hypertrophy, and morbidity associated with PAH.

Entities:  

Mesh:

Year:  2012        PMID: 22745307      PMCID: PMC3418717          DOI: 10.1182/blood-2012-03-419275

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  New onset of myelofibrosis in association with pulmonary arterial hypertension.

Authors:  Uday Popat; Adaani Frost; Enli Liu; Romelia May; Remzi Bag; Vishnu Reddy; Josef T Prchal
Journal:  Ann Intern Med       Date:  2005-09-20       Impact factor: 25.391

2.  CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities.

Authors:  Erik B Friedrich; Katrin Walenta; John Scharlau; Georg Nickenig; Nikos Werner
Journal:  Circ Res       Date:  2006-01-26       Impact factor: 17.367

3.  Angiogenesis in pulmonary hypertension with myelofibrosis.

Authors:  Eva Zetterberg; Uday Popat; Hans Hasselbalch; Josef Prchal; Jan Palmblad
Journal:  Haematologica       Date:  2008-05-06       Impact factor: 9.941

4.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima.

Authors:  S L Hazen; J W Heinecke
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

5.  Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Authors:  R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

6.  Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.

Authors:  Yidan D Zhao; David W Courtman; Yupu Deng; Lakshmi Kugathasan; Qiuwang Zhang; Duncan J Stewart
Journal:  Circ Res       Date:  2005-02-03       Impact factor: 17.367

Review 7.  Assessing identity, phenotype, and fate of endothelial progenitor cells.

Authors:  Karen K Hirschi; David A Ingram; Mervin C Yoder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

8.  Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension.

Authors:  A A Lopes; N Y Maeda
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 9.  Homing and conversion of murine hematopoietic stem cells to lung.

Authors:  Mark Dooner; Jan Cerny; Gerald Colvin; Delia Demers; Jeffrey Pimentel; Deborah Greer; Mehrdad Abedi; Christina McAuliffe; Peter Quesenberry
Journal:  Blood Cells Mol Dis       Date:  2004 Jan-Feb       Impact factor: 3.039

10.  Myeloperoxidase, a leukocyte-derived vascular NO oxidase.

Authors:  Jason P Eiserich; Stephan Baldus; Marie-Luise Brennan; Wenxin Ma; Chunxiang Zhang; Albert Tousson; Laura Castro; Aldons J Lusis; William M Nauseef; C Roger White; Bruce A Freeman
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

View more
  48 in total

Review 1.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

Review 2.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

3.  Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension.

Authors:  Jason M Elinoff; Adrien J Mazer; Rongman Cai; Mengyun Lu; Grace Graninger; Bonnie Harper; Gabriela A Ferreyra; Junfeng Sun; Michael A Solomon; Robert L Danner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-16       Impact factor: 5.464

4.  Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension.

Authors:  Ling Yan; Xinping Chen; Megha Talati; Bethany Womack Nunley; Santhi Gladson; Tom Blackwell; Joy Cogan; Eric Austin; Ferrin Wheeler; James Loyd; James West; Rizwan Hamid
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

5.  Bone Marrow-Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism.

Authors:  Nathaniel C Bloodworth; Cynthia R Clark; James D West; J Caleb Snider; Christa Gaskill; Sheila Shay; Christine Scott; Julie Bastarache; Santhi Gladson; Christy Moore; Reid D'Amico; Evan L Brittain; Harikrishna Tanjore; Timothy S Blackwell; Susan M Majka; W David Merryman
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

6.  Fulvestrant for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Steven M Kawut; Diane Pinder; Nadine Al-Naamani; Amber McCormick; Harold I Palevsky; Jason Fritz; K Akaya Smith; Jeremy A Mazurek; Margaret F Doyle; Margaret R MacLean; Angela DeMichele; David A Mankoff
Journal:  Ann Am Thorac Soc       Date:  2019-11

7.  Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation.

Authors:  Saadia A Faiz; Cezar Iliescu; Juan Lopez-Mattei; Bela Patel; Lara Bashoura; Uday Popat
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

8.  Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms.

Authors:  Emir C Roach; Margaret M Park; W H Wilson Tang; James D Thomas; Kewal Asosingh; Matt Kalaycio; Serpil C Erzurum; Samar Farha
Journal:  J Heart Lung Transplant       Date:  2014-09-28       Impact factor: 10.247

9.  Reply: Expanded Role for Bone Marrow-derived Hematopoietic Stem and Progenitor Cells in Pulmonary Arterial Hypertension.

Authors:  Ling Yan; James West; Rizwan Hamid
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

Review 10.  Origin and production of inflammatory perivascular macrophages in pulmonary hypertension.

Authors:  Jonathan Florentin; Partha Dutta
Journal:  Cytokine       Date:  2017-08-30       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.